We offer dedicated Antibody Drug Conjugate (ADC) development support and pilot-scale manufacturing for clinical studies. ADC integrates antibody engineering, linker–payload chemistry, and bioconjugation to develop targeted therapeutic candidates.
Our bioconjugation toolbox includes stochastic lysine and cysteine approaches plus site‑specific, enzymatic, glycoconjugation and click chemistries, so constructs can be tuned for homogeneity and stable performance.
We design and synthesize cleavable and non‑cleavable linkers and support a wide range of payload chemistries (for example, auristatins, maytansinoids, PBD dimers, and topoisomerase‑I payloads), and we can develop bespoke payloads or immune‑modulating conjugates as needed.
Our analytical platform supports DAR determination, conjugation‑site confirmation, free payload and unbound drug quantification, monomeric purity, serum stability, and other critical assays used to define ADC quality. We perform functional assays—binding (EC50), internalization, bystander‑effect assessment, cytotoxicity, and PK/PD studies—to de‑risk candidate selection and better define the mechanism of action.
We support small‑scale and pilot (development) batch bioconjugation and cGMP payload‑linker production to supply material for toxicology and early clinical work. To reduce operator exposure and minimize transfer‑related risk during pilot manufacture, we utilize closed, automated process solutions that combine conjugation, quenching/filtration, and tangential‑flow filtration (TFF) in a single, contained workflow suitable for R&D → pilot scale.
We provide an integrated workflow that brings together antibody production, linker/payload synthesis, conjugation, analytics, and fill‑finish in a coordinated CDMO model to shorten timelines and simplify supply‑chain complexity. Our teams and facilities are structured to handle highly potent payloads with appropriate containment and regulatory support to help progress ADC candidates from discovery to clinical supply.
Our multidisciplinary experts bridge the chemistry–biology interface to deliver robust characterization, conjugation strategy, and manufacturing plans tailored to each ADC program. We can scale development from laboratory experiments to pilot‑scale batches (liter scale) and support method transfer into larger manufacturing as projects mature toward later‑phase clinical or commercial supply.